These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
Globe Newswire (Fri, 14-Aug 1:13 PM ET)
MDXH Revenue Grows 16% in Q2 With Focused Strategy and Fresh Capital—Profitability Eyes 2026 Exit
Market Chameleon (Fri, 14-Aug 5:54 AM ET)
Mdxhealth Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 4:00 PM ET)
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
Globe Newswire (Thu, 30-Jul 4:00 PM ET)
Globe Newswire (Fri, 24-Jul 4:59 PM ET)
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Globe Newswire (Thu, 2-Jul 4:00 PM ET)
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Mdxhealth SA - trades on the NASDAQ stock market under the symbol MDXH.
As of September 8, 2026, MDXH stock price declined to $0.71 with 322,231 million shares trading.
MDXH has a beta of 3.26, meaning it tends to be more sensitive to market movements. MDXH has a correlation of 0.11 to the broad based SPY ETF.
MDXH has a market cap of $68.08 million. This is considered a Micro Cap stock.
Last quarter Mdxhealth SA - reported $27 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $4 million and met earnings estimates .
In the last 3 years, MDXH traded as high as $5.33 and as low as $.40.
The top ETF exchange traded funds that MDXH belongs to (by Net Assets): IWC.
MDXH has underperformed the market in the last year with a price return of -79.8% while the SPY ETF gained +19.2%. However, in the short term, MDXH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +18.9% vs +1.4% return in SPY. But in the last 2 weeks, MDXH shares have been beat by the market, returning -4.0% compared to an SPY return of 0.0%.
MDXH support price is $.70 and resistance is $.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDXH shares will trade within this expected range on the day.